Recce Pharmaceuticals to Receive Australian Grant
Recce receives a grant intent from the Australian Patent Office for an antivirus agent targeting mega bugs coronavirus, SARS, and HIV, growing in big pharmaceutical markets across the world.
Recce receives a grant intent from the Australian Patent Office for an antivirus agent targeting mega bugs coronavirus, SARS, and HIV, growing in big pharmaceutical markets across the world.
By Mahlia Stewart,
Lithium producers Lake Resources and Lilac Solutions have reached a major milestone at Kachi in accordance with agreed timelines.
By Mahlia Stewart,
Stellantis offers US$30 million for battery materials manufacturer Element 25 in a 45Kt offtake deal, a world-first upstream investment by a top-tier automaker to a listed manganese company.
By Mahlia Stewart,
Imugene has now crossed ethics approval off is list, and the way is now clear for clinical trials to begin in Australia.
By Mahlia Stewart,
TLEA, a co-owned entity of IGO, proposes to acquire 100% of Essential Metals Ltd, valuing it at $136 million, to expand its resource portfolio.
By Mahlia Stewart,
Westpac’s Chairman John McFarlane announces his retirement at the company’s AGM meeting, amid further Board changes and the immediate departure of Director Peter Marriott.
By Mahlia Stewart,
Santos enters a new gas supply agreement with Strike’s Walyering joint venture in the Perth Basin.
By Mahlia Stewart,
Talga is set to expand production of its silicon anode product for lithium-ion batteries in Germany after exceeding automotive and battery customer targets during the initial testing of Talnode-Si.
By Mahlia Stewart,
Ionic Rare Earths reflects on achievements in 2022 and prepares for alignment of strategies to take effect in the first half of 2023 for its Makuutu Project in Uganda.
By Mahlia Stewart,
CEO of CSL Paul Perreault prepares to pass the baton to the company’s incoming successor, but not until March next year. Perreault will be retiring after 25 years with the company.
By Mahlia Stewart,
Investment ideas from the edge of the bell curve.
Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.
All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.
The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.
Fat Tail Daily is brought to you by the team at Fat Tail Investment Research
Copyright © 2026 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988